$591 | SAVE $104 | Single User
$2423 | SAVE $427 | Site License
$4803 | SAVE $847 | Global License

Orphan Drug Market Access: Payer Insights on the Present and Future
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 14 Oct 2014 | 163 | In Stock
Related Topics: Orphan Drugs , Pharmacy

Introduction

Introduction


Orphan Drug Market Access: Payer Insights on the Present and Future is a report that examines the regulation, pricing, reimbursement, players and stakeholder/payer interests that are shaping the current and future direction of the orphan drug sector.


The number of orphan drug approvals is growing and access for patients is wide. There is little by way of price constraint with cost per patient year exceeding US0,000 in some cases. Orphan drugs bring benefits for critically ill patients and profit for companies. So...


Can the good times last?


There is fear from healthcare payers that the rising number of products, treatment cost and unrestricted access is unsustainable. Many orphan drugs are label extensions of mainline treatments while better understanding of the genetic basis of disease is naturally creating ever smaller patient populations for highly-targeted therapies. As genetic research advances, it is possible to imagine a time when the majority of new drugs would meet orphan drug criteria. Orphan Drugs are part of the clinical landscape and all stakeholders have valid interests which have to be addressed now.


Orphan Drug Market Access: Payer Insights on the Present and Future offers insights from US and European healthcare payers and includes illustrative case studies that highlight key aspects of the orphan drug market.


Puchase Reasons


Key Benefits


  • Profile leading markets in respect to your orphan drug projects and know the points of difference in their pricing/reimbursement mechanisms and regulatory requirements.

  • Identify which therapy areas are driving growth in the orphan drug space and what that means for your business and plans.

  • Competitively evaluate the companies most active in the field in terms of revenue performance and research.

  • Address the rising and legitimate concerns of healthcare payers in US and Europe about cost, pricing policies, value for money, indication expansion and the lack of positive engagement with industry.

  • Practically plan for likely strategic challenges in orphan drugs such as funding caps and HTA assessments.

  • Get Answers to Critical Questions


  • What does the regulatory environment in the US and Europe look like?

  • What is the current and future market value?

  • What therapy areas are of importance?

  • What is the pricing and reimbursement structure for orphan drugs in US, France, Germany, Italy, Spain and the UK?

  • What are the payers’ views and how can industry positively respond to rising concerns around cost, clinical data and involvement in the research process?

  • Which future market developments may pose challenges? (ie: risk sharing, HTA assessment, a less benign view of funding, post marketing cost benefit justification and the influence of patient advocacy groups.)

  • Experts Interviewed


  • UK payer – Advisor to NHS organisations (e.g. CCGs)

  • UK payer - Head of medicines optimisation for a large CCG, UK

  • Germany payer – Pharmacist

  • Italy payer – Pharmacist on Hospital Formulary Committee and Regional Formulary Committee

  • Spain payer – Director of Hospital Pharmacies, Member of Medication of High Impact Committee, Chief of the Pharmacy, Chief of the Pharmacy Therapeutic Committee

  • France payer – Pharmacist

  • US payer – Executive vice-president of pharmacy for national US PBM

  • US payer – Professor of Medicine, health policy researcher and lawyer with a special interest in orphan drugs

  • Key Quotes


    “There’s a central committee with a president and a vice-president, and groups of medical experts for oncology and other fields. As soon as new drugs are released, we first ask the experts for their opinion. They tell us what they think about the new products compared to the existing treatments. This opinion is then sent to the central committee that then discusses whether or not to add the product to our formulary.” Pharmacist, France


    “We're going to have to start looking at different risk scenarios with pharmaceutical manufacturers,” Executive Vice President of pharmacy for national PBM, US


    “We get very little notification from them. We get very little detail about what's coming to market. It's generally a reactive process rather than something we seek out proactively.” 
Head of medicines optimisation, CCG, UK


    “It's always helpful if we see data or we see summaries where it's clear this new drug is working … In my eyes that is very critical in the discussion at the moment. Nobody really talks about how much money can we save and how many people are cured by this new drug”. 
Pharmacist, Germany

    Table of Contents
    for Orphan Drug Market Access: Payer Insights on the Present and Future [Published by FirstWord Pharma]

    • 1.Executive summary

      1.1.There are generally few pricing and reimbursement limitations on orphan drugs

      1.2.Payers believe the orphan drug designation is being taken advantage of in some cases

      1.3.Payers currently have limited engagement with the pharmaceutical industry on orphan drugs

      1.4.Market access is likely to present a growing challenge for orphan drugs in the future

      2.Research objectives and methodology

      3.Orphan drugs and rare diseases overview

      3.1.Section summary

      3.2.What are orphan drugs?

      3.3.The regulatory environment

      3.3.1.US

      3.3.1.1.The Orphan Drug Act set a regulatory process in place for orphan drugs in the US

      3.3.1.2.The approval of orphan drugs is subject to a separate process

      3.3.2.EU

      3.3.2.1.The EU regulations have established incentives for orphan drug development

      3.3.2.2.Access to orphan drugs can be varied across Europe

      3.4.Current market dynamics

      3.4.1.The size of the orphan drugs market has increased significantly in recent years

      3.4.1.1.Therapy areas

      3.4.1.2.The big pharmaceutical companies all have significant orphan drug interests

      3.4.2.The market is forecast to grow considerably

      3.4.2.1.A range of important new orphan drugs has been launched in the last two years

      3.4.2.2.The pipeline for orphan drugs is expected to deliver some promising new therapies

      3.5.Orphan drugs undergo the same pricing and reimbursement process as

      other products in most markets

      3.5.1.US

      3.5.2.France

      3.5.2.1.There are several fast track procedures in place to encourage faster access

      to new treatments

      3.5.3.Germany

      3.5.4.Italy

      3.5.4.1.The standard pricing and reimbursement process will usually allow for full

      reimbursement of orphan drugs

      3.5.4.2.There are two special mechanisms in place for the pricing and reimbursement

      of orphan drugs

      3.5.5.Spain

      3.5.5.1.There are mechanisms in place to encourage earlier access to orphan drugs

      3.5.6.UK

      3.5.6.1.The HTA process is of critical importance in the UK

      3.5.6.2.Local level decisions impact on orphan drug use

      4.Payer insights on orphan drugs

      4.1.Summary and key insights

      4.2.The extremely high price that orphan drugs command is an increasing concern for payers

      4.2.1.The rising prices of orphan drugs are raising concerns over future funding

      4.2.2.Obtaining approval for use in a rare disease is seen as a way to increase the

      price for some drugs

      4.3.Payers feel that some companies are taking advantage of the orphan drug designation

      4.3.1.Indication expansion after initial approval is a key frustration for payers

      5.Needs and requirements for orphan drugs

      5.1.Summary and key insights

      5.2.There is a limited level of decision making for orphan drugs

      5.2.1.Individual funding requests require UK payers to make decisions on orphan drugs

      5.2.2.There are generally no restrictions on accessing orphan drugs in the US

      5.2.3.The variation in clinical data available for orphan drugs can impact on decision making

      5.2.4.Comparative data is generally not available, making health economic

      assessments challenging

      5.3.Engagement with pharmaceutical companies on orphan drugs is limited

      5.3.1.Pharmaceutical companies rarely solicit advice from payers when

      developing orphan drugs

      5.3.2.Best case examples

      5.3.3.Payers would like the pharmaceutical industry to be more engaged on orphan drugs

      5.3.3.1.Payers would like to start receiving data whilst the drug is still in clinical trials

      5.3.3.2.A range of data is required, including budget impact, epidemiology and

      expected usage

      6.Future expectations

      6.1.Summary and key insights

      6.2.The competitive landscape for orphan diseases is expected to continue to develop

      6.3.Market access is expected to become increasingly challenging

      6.3.1.HTA assessments may start to be applied for orphan drugs

      6.3.2.Risk-share may be required for continued funding of orphan drugs

      6.4.How pharma companies can ensure continued opportunities for orphan drugs

      6.4.1.Patient advocacy is expected to become more important

      6.4.2.Ensuring outcomes are being collected will help justify the high price of orphan drugs

      7.Contributors

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    163 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 15% today! Global Orphan Diseases Partnering 2010-2016: Deal trends, players and financials
    Global Orphan Diseases Partnering 2010 to 2016 provides the full collection of Orphan Diseases disea...
    01 Oct 2016 by Current Partnering USD $2,546 (normally
    USD $2,995)
    More Info
    SAVE 15% today! Swedish Orphan Biovitrum Partnering Deals and Alliances 2010 to 2016
    The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
    01 Oct 2016 by Current Partnering USD $1,271 (normally
    USD $1,495)
    More Info
    SAVE 15% today! Orphan Drug Commercialisation and Market Access in Emerging Markets
    IntroductionMarket access for orphan drugs: Can your company break through in emerging markets?Find ...
    01 Jul 2016 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Orphan Drug Commercial Models: Sustaining the rare disease business
    IntroductionChoosing the right commercial model for orphan drug successThe societal and commercial a...
    01 May 2016 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Patient Engagement in Orphan Drugs
    IntroductionWhy is the patient voice critical to orphan drug success?Patient input is critical to an...
    01 Apr 2016 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Aop Orphan Pharmaceuticals AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    SummaryAOP Orphan Pharmaceuticals AG (AOP Orphan) is a research-oriented pharmaceutical company whic...
    09 Mar 2016 by Global Data USD $213 (normally
    USD $251)
    More Info
    SAVE 15% today! Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review
    Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review provides you an in...
    15 Dec 2015 by Global Data USD $106 (normally
    USD $125)
    More Info
    SAVE 15% today! Commercial Excellence in Rare Diseases and Orphan Drugs
    IntroductionDeveloping therapies for orphan diseases is attracting much industry interest with the p...
    01 Jun 2015 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Market Access for Orphan Drugs: assessing the global landscape
    IntroductionTheir development costs can be high and the market is relative small, yet orphan drugs r...
    01 Dec 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Effective Sales and Marketing Strategies for Orphan Drugs
    IntroductionThe real potential for orphan drug pharma marketingWith drug pipelines moving from essen...
    01 Jun 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Orphan Drug Market Access: Payer Insights on the Present and Future [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...